Abstract:Glioblastoma multiforme (GBM)is the most common and aggressive primary brain tumor. Although temozolomide (TMZ)-based radiochemotherapy improves overall GBM patients' survival, it also increases the frequency of false positive post-treatment magnetic resonance imaging (MRI) assessments for tumor progression. Pseudo-progression (PsP) is a treatment-related reaction with an increased contrast-enhancing lesion size at the tumor site or resection margins miming tumor recurrence on MRI. The accurate and reliable prognostication of GBM progression is urgently needed in the clinical management of GBM patients. Clinical data analysis indicates that the patients with PsP had superior overall and progression-free survival rates. In this study, we aimed to develop a prognostic model to evaluate the tumor progression potential of GBM patients following standard therapies. We applied a dictionary learning scheme to obtain imaging features of GBM patients with PsP or true tumor progression (TTP) from the Wake dataset. Based on these radiographic features, we conducted a radiogenomics analysis to identify the significantly associated genes. These significantly associated genes were used as features to construct a 2YS (2-year survival rate) logistic regression model. GBM patients were classified into low- and high-survival risk groups based on the individual 2YS scores derived from this model. We tested our model using an independent The Cancer Genome Atlas Program (TCGA) dataset and found that 2YS scores were significantly associated with the patient's overall survival. We used two cohorts of the TCGA data to train and test our model. Our results show that the 2YS scores-based classification results from the training and testing TCGA datasets were significantly associated with the overall survival of patients. We also analyzed the survival prediction ability of other clinical factors (gender, age, KPS (Karnofsky performance status), normal cell ratio) and found that these factors were unrelated or weakly correlated with patients' survival. Overall, our studies have demonstrated the effectiveness and robustness of the 2YS model in predicting the clinical outcomes of GBM patients after standard therapies.

Identification of a novel glioblastoma multiforme molecular subtype with poor prognosis and high immune infiltration based on oxidative stress-related genes

Immunological Classification of Glioblastoma and Its Prognostic Implications.

Integrated Analysis of Multiomics Data Identified Molecular Subtypes and Oxidative Stress-Related Prognostic Biomarkers in Glioblastoma Multiforme

Identification of Novel Human Glioblastoma-Specific Transcripts by Serial Analysis of Gene Expression Data Mining

Multi-Omics Analysis Reveals Novel Subtypes and Driver Genes in Glioblastoma

Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition

Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and Therapy

Molecular Characteristics in MRI-Classified Group 1 Glioblastoma Multiforme

Metabolic Modeling Identifies a Novel Molecular Type of Glioblastoma Associated with Good Prognosis.

Identification of Immune Cell Infiltration and Immune-Related Genes in the Tumor Microenvironment of Glioblastomas

Identification and validation of ion channels-related mRNA prognostic signature for glioblastomas

Prognostic Value and Immune Cell Infiltration of Hypoxic Phenotype‐related Gene Signatures in Glioblastoma Microenvironment

Radiogenomics-Based Risk Prediction of Glioblastoma Multiforme with Clinical Relevance

Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma

Genome-wide Expression Profiling of Glioblastoma Using a Large Combined Cohort.

Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance

Path-27. Molecular, Imaging, And Survival Manifestations In Molecular Glioblastomas: Insights From A Multi-National Study

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors

Novel Biomarker Genes for Prognosis of Survival and Treatment of Glioma

Immune landscape-based machine-learning-assisted subclassification, prognosis, and immunotherapy prediction for glioblastoma